Publications of James M. Sheil, PhD

Propanil exposure induces delayed but sustained abrogation of cell-mediated immunity through direct interference with cytotoxic T-lymphocyte effectors.
Sheil JM, Frankenberry MA, Schell TD, Brundage KM, Barnett JB.
Environ Health Perspect. 2006;114(7):1059-1064.

PMC1513295.

Superantigens and their role in infectious disease.
Schafer R, Sheil JM.
Adv Pediatr Infect Dis. 1995;10:369-390.


Evidence that the antigen receptors of cytotoxic T lymphocytes interact with a common recognition pattern on the H-2Kb molecule.
Sun R, Shepherd SE, Geier SS, Thomson CT, Sheil JM, Nathenson SG.
Immunity. 1995;3(5):573-582.


Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
Sheil JM, Schell TD, Shepherd SE, Klimo GF, Kioschos JM, Paterson Y.
Eur J Immunol. 1994;24(9):2141-2149.


Minor pocket B influences peptide binding, peptide presentation and alloantigenicity of H-2Kb.
Yun TJ, Tallquist MD, Rohren EM, Sheil JM, Pease LR.
Int Immunol. 1994;6(7):1037-1047.


Peptide competition studies suggest the possible binding of 2 Ctl-recognized peptides to a single class-I Mhc molecule.
Schell T, Paterson Y, Sheil JM.
J Immunol. 1993;150(8):A39-A39.


Identification of an autologous insulin B chain peptide as a target antigen for H-2Kb-restricted cytotoxic T lymphocytes.
Sheil JM, Shepherd SE, Klimo GF, Paterson Y.
J Exp Med. 1992;175(2):545-552.

PMC2119120.

Selective reactivity of CD8-independent T lymphocytes to a cytotoxic T lymphocyte-selected H-2Kb mutant altered at position 222 in the alpha 3 domain.
Shepherd SE, Sun R, Nathenson SG, Sheil JM.
Eur J Immunol. 1992;22(3):647-653.


Use of mutants to analyze regions on the H-2Kb molecule for interaction with immune receptors.
Nathenson SG, Kesari K, Sheil JM, Ajitkumar P.
Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:521-528.


Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides.
Carbone FR, Moore MW, Sheil JM, Bevan MJ.
J Exp Med. 1988;167(6):1767-1779.

PMC2189675.

Class I-restricted cytotoxic T-cell responses to a soluble-protein antigen.
Bevan MJ, Carbone FR, Sheil JM, Wegmann DR.
J Cell Biochem. 1987;202-202.


Characterization of dual-reactive H-2Kb-restricted anti-vesicular stomatitus virus and alloreactive cytotoxic T cells.
Sheil JM, Bevan MJ, Lefrancois L.
J Immunol. 1987;138(11):3654-3660.


Generation of Ovalbumin-specific, class I-restricted cytotoxic lymphocytes-T.
Sheil JM, Carbone FR, Wegmann DR, Bevan MJ.
Fed Proc. 1987;46(4):1343-1343.


Immunoselection of structural H-2Kb variants: use of cloned cytolytic T cells to select for loss of a CTL-defined allodeterminant.
Sheil JM, Bevan MJ, Sherman LA.
Immunogenetics. 1986;23(1):52-59.


Susceptibility of Adenovirus 2-transformed rat cell lines to natural killer (NK) cells: direct correlation between NK resistance and in vivo tumorigenesis.
Sheil JM, Gallimore PH, Zimmer SG, Sopori ML.
J Immunol. 1984;132(3):1578-1582.


Heterogeneity among cyto-toxic target determinants on adenovirus-2 (Ad 2)-transformed cell-lines.
Sheil JM, Sopori ML, Zimmer SG.
Fed Proc. 1981;40(3):1149-1149.


T-lymphocyte heterogeneity in rat: role of adherent T-cell subpopulation in the regulation of cytotoxic T-cell response to alloantigens.
Sopori ML, Sheil JM, Roszman TL, Brooks WH.
Cell Immunol. 1981;65(1):103-114.


Evidence for reduction of the leukocyte chemotactic response to endotoxin by human platelets.
Sheil JM, Walker RI.
Toxicon. 1979;17(2):173-176.


Biologic properties of bacterial lipopolysaccharides treated with chromium chloride.
Snyder SL, Walker RI, MacVittie TJ, Sheil JM.
Can J Microbiol. 1978;24(5):495-501.


Peritoneal macrophage chemotactic response and accumulation in mice injected with Lewis Lung (3Ll) carcinoma cells.
Sheil JM, Crawford RM, Ledney CD.
Exp Hematol. 1976;4:127-127.


Contribution of granulocytopenia to endotoxin sensitivity of mice irradiated or undergoing graft-versus-host reaction.
Walker RI, Sheil JM.
Exp Hematol. 1976;4(6):329-338.